Big Pharma got burned in pandemics past. CEPI believes this time will be different
Time after time, when a pandemic strikes the world, major drug makers have reshuffled their priorities and fast-tracked potential vaccines only to find themselves holding the bag when demand dissipates, governments don’t want to pay, and public perception turns on the industry.
That’s made the world’s largest pharmaceutical firms skittish about embarking on vaccine research during an outbreak. But according to Richard Hatchett, CEO of a foundation devoted to pandemic preparedness, that won’t be a problem when it comes to the novel coronavirus.
Speaking to STAT’s Helen Branswell, Hatchett said all of the major drug companies have signaled that they want to help his organization, the Coalition for Epidemic Preparedness Innovations, whether by developing vaccines of their own or lending expertise to others.
“I will say that many of those manufacturers had over many years, whether it was with Zika or Ebola or dengue, had a series of experiences that somewhat disincentivized their participation in developing vaccines against epidemic diseases,” Hatchett said. “This is different. This is an extraordinary historical event of unbelievable proportions. And I don't think that the kinds of considerations that make them not want to jump into Ebola vaccine development are operative here.”
Read more.
That’s made the world’s largest pharmaceutical firms skittish about embarking on vaccine research during an outbreak. But according to Richard Hatchett, CEO of a foundation devoted to pandemic preparedness, that won’t be a problem when it comes to the novel coronavirus.
Speaking to STAT’s Helen Branswell, Hatchett said all of the major drug companies have signaled that they want to help his organization, the Coalition for Epidemic Preparedness Innovations, whether by developing vaccines of their own or lending expertise to others.
“I will say that many of those manufacturers had over many years, whether it was with Zika or Ebola or dengue, had a series of experiences that somewhat disincentivized their participation in developing vaccines against epidemic diseases,” Hatchett said. “This is different. This is an extraordinary historical event of unbelievable proportions. And I don't think that the kinds of considerations that make them not want to jump into Ebola vaccine development are operative here.”
Read more.
.png)
No hay comentarios:
Publicar un comentario